Studies have shown that HER2 overexpression or amplification was observed in 20% of GC patients, and the HER2-positive rate of gastroesophageal junction (GEJ) cancer (32.2%) was higher than that of gastric tumors (21.4%) (Van Cutsem et al., 2015). This evidence concerns the gene ERBB2 and gastric cancer.